SAN DIEGO — MitraClip plus maximally-tolerated guideline-directed medical therapy (GDMT) proved to be a significantly more effective treatment for patients with heart failure (HF) and moderate to severe secondary mitral regurgitation (MR) compared to GDMT alone, according to results of the highly anticipated COAPT trial released Sunday at the Transcatheter Cardiovascular Therapeutics (TCT) conference.